Liansheng Li

USPTO Granted Patents = 114 (Patent Applications = 55)

CIPO Patents = 9 (Patent Applications = 23)

EPO Patents = 33 (Patent Applications = 71)

Average Co-Inventor Count = 6.1

ph-index = 28

Forward Citations = 1,825(Granted Patents)

Inventors with similar research interests:

Location History:

La Jolla, CA (US) (2019)
San Diego, CA (US) (2008 - 2024)

Company Filing History:

Infinity Pharmaceuticals, Inc.

patents

5. 10 out of 3,370

University of Michigan

patents

6. 5 out of 51

Anadys Pharmaceuticals, Inc.

patents

7. 4 out of 7

Kumquat Biosciences Inc.

patents

8. 2 out of 410

Janssen Biotech, Inc.

patents

9. 1 out of 15,458

University of California

Millennium Pharmaceuticals Limited

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

114 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. RE50527 - Covalent inhibitors of KRAS G12C (2025-08-12),

2. 12365676 - Heterocyclic compounds and uses thereof (2025-07-22),

3. RE50490 - Substituted quinazoline compounds and methods of use thereof (2025-07-15),

4. 12286427 - Heterocyclic compounds and uses thereof (2025-04-29),

5. 12234244 - Substituted piperazines as inhibitors of KRAS G12C (2025-02-25),

6. 12209102 - Heterocyclic compounds and uses thereof (2025-01-28),

7. 12134620 - Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer (2024-11-05),

8. 12059425 - Heterocyclic compounds and uses thereof (2024-08-13),

9. 11944627 - Methods for treating hematological malignancies and Ewing's sarcoma (2024-04-02),

10. 11878985 - Substituted quinazolines as inhibitors of KRAS G12C (2024-01-23),

11. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

12. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

13. 11649251 - Substituted inhibitors of menin-MLL and methods of use (2023-05-16),

14. 11639346 - Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS (2023-05-02),

15. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

Title: Inventor Spotlight: Liansheng Li

Introduction: Liansheng Li, a prolific inventor based in San Diego, CA, has made significant contributions to the field of medicine with an impressive tally of 106 patents to his name.

Latest Patents:

1. Methods for treating hematological malignancies and Ewing's sarcoma - Liansheng Li's latest patent focuses on utilizing menin inhibitors to treat hematological malignancies and Ewing's sarcoma, offering new hope in the fight against these diseases.

2. Substituted quinazolines as inhibitors of KRAS G12C - Another recent patent by Li involves compounds that act as inhibitors of G12C mutant KRAS protein, providing potential avenues for cancer treatment.

Career Highlights: Liansheng Li has honed his expertise while working at companies like Araxes Pharma LLC and Intellikine LLC, where he has undoubtedly played a pivotal role in advancing medical research and innovation.

Collaborations: Throughout his career, Li has collaborated with talented individuals such as Pingda Ren and Yi Liu, showcasing his ability to work effectively in teams and drive innovation through collective efforts.

Conclusion: Liansheng Li's remarkable journey as an inventor underscores his commitment to pushing the boundaries of medical science and finding novel solutions to complex healthcare challenges. His innovative patents stand testament to his dedication and prowess in the field of medicine, making him a true trailblazer in the realm of innovation.

This text is generated by artificial intelligence and may not be accurate.